Sellas stock nearly triples as its leukemia vaccine cuts risk of death 41% in a Phase 3 trial
SELLAS says galinpepimut-S met its primary survival goal in the REGAL trial: 24.0 months median survival versus 14.7 on best available treatment. The result is topline, and the p-value is 0.035.
SELLAS Life Sciences (NASDAQ: SLS) said Tuesday that its cancer vaccine galinpepimut-S, or GPS, met the primary endpoint of the pivotal Phase 3 REGAL trial in acute myeloid leukemia (AML). The shares were trading at $20.22 at 12:41 p.m. ET, up 170.7% from Monday's $7.47 close, according to Nasdaq quote data. Bloomberg and Benzinga both described the move as the stock tripling at its peak; Nasdaq showed a session range of $16.72 to $24.89.
What the company reported
In its press release filed with the SEC, SELLAS said:
- GPS cut the risk of death by 41%, a hazard ratio of 0.59, with a two-sided p-value of 0.035.
- Median overall survival was 24.0 months for GPS versus 14.7 months for investigator's choice of best available treatment.
- The patients had AML in second or later complete remission and could not have, or could not undergo, an allogeneic stem cell transplant. GPS was given as maintenance monotherapy.
- The analysis was run after the pre-specified 80 deaths, under the trial's statistical plan.
- Safety was "generally well tolerated," with mostly grade 1 or 2 events, mainly injection-site reactions, and no new safety signals.
What it means, and what it does not
A median gain of about 9.3 months (24.0 less 14.7, our arithmetic) in a group with few options is a large effect if it holds. But three caveats matter for anyone reading the stock move:
- It is topline data. The company says secondary endpoints and other pre-specified analyses are still being evaluated and will be presented at a medical meeting and submitted for peer review. Nobody outside the company has seen the full dataset.
- The p-value is close to the usual line. A p of 0.035 clears the conventional 0.05 threshold, but not by much. Small trials with few events can move on a handful of patients.
- The regulatory path is not set. SELLAS says it plans to meet the FDA about an "accelerated filing strategy" and is preparing a Biologics License Application for the first half of 2027. A meeting is not an agreement, and the FDA has not commented in the filing.
The market side
Nasdaq lists a market value of about $4.13 billion at the current price, and a 52-week low of $1.39. For a clinical-stage company, a first Phase 3 win can change how it raises money: the share price now sets the terms for any stock offering or partnership. Whether SELLAS does either is not in the filing, and we do not report it as a plan.
For small-cap biotech holders, the rest of the week is about the webcast replay, any FDA feedback and whether the full secondary-endpoint data match the headline. Related reading: more stock news.
Sources: SELLAS 8-K, Nov. 17, 2026; SELLAS filings on SEC EDGAR; price data from Nasdaq, read at 12:41 p.m. ET; Bloomberg and Benzinga headlines. Investigational therapies are not approved by the FDA. This is market information, not investment advice.
Want your business to be the answer?
Get a full package of articles about your business, built so customers, Google and AI assistants can find you.
New ebook from The Company ChronicleHow to Research Like a Wall Street AnalystFind original sources, analyze trends, and build your own insights. 36 pages with worksheets.Get the ebook · $29Instant PDF download

